Mr. Speaker, I would like to thank my hon. colleague for acknowledging that vaccinations in indigenous communities has been a priority for this government. It will continue to be so.
In terms of her question relating to domestic production, our procurement has proceeded along two tracks. The first track has been under my purview, which is to ensure that we have vaccines coming into the country from international suppliers. On the second track, relating to domestic production, we have put $126 million into the NCR facility in Montreal for the production of vaccines domestically. We have signed an MOU with Moderna for the production of vaccines at that facility.
In addition, we have signed an APA with Medicago in Quebec. That company is in the third phase of clinical trials. We will continue to enhance and invest in the domestic production of vaccines, but it is a two-track approach. We need to make sure that we have vaccines here as soon as possible. That is why we are going to be seeing millions and millions of doses coming into the country, 48 million to 50 million doses prior to the end of June, and Pfizer is delivering two million doses or more—